Basic Information
NovoMix
Regulatory Information
EMEA/H/C/000308
August 1, 2000
April 13, 2000
29
August 29, 2023
Company Information
Denmark
Novo Allé DK-2880 Bagsværd
Novo Nordisk A/S
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of diabetes mellitus.
Overview Summary
NovoMix is a range of insulin medicines used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled. NovoMix medicines contain the active substance insulin aspart (100 units/ml) combined with protamine to make it longer acting. It is available as: - NovoMix 30 (30% insulin aspart and 70% insulin aspart protamine) - NovoMix 50 (50% insulin aspart and 50% insulin aspart protamine) - NovoMix 70 (70% insulin aspart and 30% insulin aspart protamine). NovoMix 30 can be used in patients from 10 years of age. NovoMix 50 and NovoMix 70 can only be used in adults (from 18 years of age).